Ascletis Pharma Inc. (Ascletis) (HKEX: 1672), a fully integrated biotechnology company, announced on Sunday that it has dosed its first participant in a global Phase III clinical programme of ASC30 for chronic weight management.
ASC30 is an investigational, proprietary once-daily oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is developed for chronic weight management and diabetes.
The global Phase III clinical programme includes two pivotal, multicentre, randomised, double-blind, placebo-controlled Phase III trials - AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450) - assessing the long-term efficacy, safety, and tolerability of ASC30 once-daily oral tablets in around 4,600 participants across the US, Europe, and Canada.
Ascletis plans to reveal top-line data from the programme in the third quarter of 2028. It is expected to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) by the end of 2028 and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in early 2029.
Annovis Bio schedules corporate update webinar for next week
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Vanda's imsidolimab
United Therapeutics wins FDA acceptance for ralinepag PAH filing
Acadia wins EU approval for DAYBU as first treatment for Rett syndrome
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer
European Commission grants orphan designation for Lundbeck's asedebart
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance